- Recommendation ID
- NG28/04
- Question
Long-term outcomes associated with blood glucose lowering agents: In adults with type 2 diabetes, what are the long‑term effects of blood glucose lowering therapies such as dipeptidyl peptidase‑4 (DPP‑4) inhibitors, sodium–glucose cotransporter‑2 (SGLT2) inhibitors and meglitinides?
- Any explanatory notes
(if applicable) Why this is important?
There is limited evidence in relation to the long‑term effects (at least 5 years) of blood glucose lowering therapies, particularly newer agents in terms of efficacy and adverse events (for example, cardiovascular outcomes). Randomised controlled trials and prospective longitudinal studies are needed to better understand the long‑term efficacy and safety issues surrounding these medicines.
Source guidance details
- Comes from guidance
- Type 2 diabetes in adults: management
- Number
- NG28
- Date issued
- December 2015
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 30/11/2021 |